The present invention relates to the combination of spirulina and palmitoylethanolamide (PEA) and/or pharmaceutically acceptable derivates or salts thereof, pharmaceutical formulations comprising the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof, optionally together with at least one physiologically acceptable excipient, and the use of the combination of spirulina and PEA and/or pharmaceutically acceptable derivates or salts thereof and formulations which include the said combination, for use in the prevention and/or treatment of tissue hyperactivation states, in the prevention and/or treatment of inflammatory pathologies, in the prevention and/or treatment of alterations in cardiac and/or coronary tissue, in the prevention and/or treatment of alterations in the vascular tissue, in the prevention and/or treatment of ophthalmic pathologies, preferably in the prevention and/or treatment of macular degeneration pathologies and glaucoma, in the prevention and/or treatment of dyslipidemia, in the prevention and/or treatment of alterations in pulmonary tissue, in the prevention and/or treatment of alterations in pelvic tissues, in the prevention and/or treatment of cellular alterations due to carcinogenesis, and/or in the prevention and/or treatment of dermatological alterations.
